How These Biotech Stocks are Performing? -- Inovio Pharma, Intra Cellular Therapies, OncoMed Pharma, and Ophthotech

Friday, July 28, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 28, 2017 /PRNewswire/ --

If you want a Stock Review on INO, ITCI, OMED, or OPHT then come over to and sign up for your free customized report today. On Thursday, July 27, 2017, the NASDAQ Composite and the S&P 500 edged 0.63% and 0.10% lower, respectively at the closing
bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.39%. US markets saw a mixed session as 4 sectors closed in green, 4 sectors finished in red, and 1 sector ended flat for the day. Taking into consideration yesterday's market sentiment, assessed the following Biotechnology equities this morning: Inovio Pharmaceuticals Inc. (NASDAQ: INO), Intra-Cellular Therapies Inc. (NASDAQ: ITCI), OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), and Ophthotech Corp. (NASDAQ: OPHT). Learn more about these stocks by registering for free on and accessing the complimentary research reports at:

Inovio Pharma 

On Friday, shares in Plymouth Meeting, Pennsylvania headquartered Inovio Pharmaceuticals Inc. recorded a trading volume of 3.24 million shares, which was higher than their three months average volume of 1.96 million shares. The stock ended at $5.51, declining 7.24% from the last trading session. The stock is trading below its 50-day moving average by 27.71%. Furthermore, shares of Inovio Pharma, which develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases, have a Relative Strength Index (RSI) of 19.20. See our free and comprehensive research report on INO at:

Intra Cellular Therapies 

New York headquartered Intra-Cellular Therapies Inc.'s stock finished yesterday's session 5.36% lower at $11.66. A total volume of 303,367 million shares was traded. The stock is trading above its 50-day moving average by 2.76%. Furthermore, shares of Intra-Cellular Therapies, which engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease, have an RSI of 45.00. ITCI free research report PDF is just a click away at:

OncoMed Pharma 

At the close of trading on Friday, shares in Redwood City, California headquartered OncoMed Pharmaceuticals Inc. saw a decline of 7.26%, ending the day at $3.32. The stock recorded a trading volume of 250,539 shares. The stock is trading below its 50-day moving average by 6.28%. Moreover, shares of OncoMed Pharma, which discovers and develops cancer stem cell and immuno-oncology therapeutics, have an RSI of 41.88. Sign up for your complimentary report on OMED at:


New York headquartered Ophthotech Corp.'s shares ended the day 6.64% lower at $2.53 with a total trading volume of 830,080 shares, which was above their three months average of 676.17 thousand shares. The Company's shares are trading below their 50-day moving average by 2.69%. Additionally, shares of Ophthotech, which develops novel therapeutics to treat diseases of the back of the eye, have an RSI of 44.92. Register for free on and download the latest research report on OPHT at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store